skip navigation

Skip Nav

Clinical Guidelines Portal

skip navigation

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

Panel Roster

(Last updated:2/12/2013; last reviewed:2/12/2013)


 

HHS Panel on Antiretroviral Guidelines for Adults and Adolescents Panel Roster
 These Guidelines were developed by the Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents (a Working Group of the Office of AIDS Research Advisory Council).
   
 Panel Co-Chairs  
 John G. Bartlett Johns Hopkins University, Baltimore, MD 
 H. Clifford Lane National Institutes of Health, Bethesda, MD
 Executive Secretary  
 Alice K. Pau National Institutes of Health, Bethesda, MD
 Scientific Members  
 Judith Aberg  New York University, New York, NY
 Adaora Adimora  University of North Carolina, Chapel Hill, NC
 John T. Brooks  Centers for Disease Control and Prevention, Atlanta, GA
 Deborah L. Cohan  University of California–San Francisco, San Francisco, CA
 Eric Daar  University of California–Los Angeles, Harbor-UCLA Medical Center, Los Angeles, CA
 Steven G. Deeks  University of California–San Francisco, San Francisco, CA
 Carlos del Rio  Emory University, Atlanta, GA
 Robert T. Dodge  University of North Carolina, Chapel Hill, NC
 Courtney V. Fletcher   University of Nebraska Medical Center, Omaha, NE
 Gerald Friedland  Yale University School of Medicine, New Haven, CT
 Joel E. Gallant  Johns Hopkins University, Baltimore, MD
 Stephen J. Gange  Johns Hopkins University, Baltimore, MD
 Christopher M. Gordon  National Institutes of Health, Bethesda, MD
 Roy M. Gulick  Weill Medical College of Cornell University, New York, NY
 W. Keith Henry  Hennepin County Medical Center & University of Minnesota, Minneapolis, MN
 Michael D. Hughes  Harvard School of Public Health, Boston, MA
 Bill G. Kapogiannis  National Institutes of Health, Bethesda, MD
 Daniel R. Kuritzkes  Brigham and Women’s Hospital & Harvard Medical School, Boston, MA 
 Richard W. Price  University of California–San Francisco, San Francisco, CA
 Michael Saag  University of Alabama at Birmingham, Birmingham, AL
 Paul Sax  Brigham and Women’s Hospital & Harvard Medical School, Boston, MA
 Mark Sulkowski  Johns Hopkins University, Baltimore, MD
 Zelalem Temesgen  Mayo Clinic, Rochester, MN
 Phyllis Tien  University of California–San Francisco, San Francisco, CA
 Rochelle Walensky  Massachusetts General Hospital & Harvard Medical School, Boston, MA
 David A. Wohl  University of North Carolina, Chapel Hill, NC
 Community Members  
 Lei Chou  Treatment Action Group, New York, NY
 Paul Dalton  San Francisco, CA
 Heidi Nass  University of Wisconsin, Madison, WI
 Jeff Taylor  AIDS Treatment Activists Coalition, Palm Springs, CA
 Nelson Vergel  Program for Wellness Restoration, Houston, TX
 Members Representing Department of Health and Human Services Agencies
 Victoria Cargill  National Institutes of Health, Rockville, MD
 Laura Cheever  Health Resources and Services Administration, Rockville, MD
 Jonathan Kaplan   Centers for Disease Control and Prevention, Atlanta, GA
 Kendall Marcus  Food and Drug Administration, Silver Spring, MD
 Henry Masur   National Institutes of Health, Bethesda, MD
 Lynne Mofenson   National Institutes of Health, Bethesda, MD
 Kimberly Struble  Food and Drug Administration, Silver Spring, MD
 Non-Voting Observer  
 Monica Calderon  National Institutes of Health, SAIC-Frederick, Inc., NCI-Frederick, Frederick, MD
 Acknowledgement  
 The Panel would like to acknowledge the assistance of Sarita D. Boyd, Pharm.D. (Food and Drug Administration) for her assistance in updating the drug interaction tables, and Thomas Uldrick, M.D. (National Cancer Institute) for his assistance with the Malignancies discussion located in the Initiating Antiretroviral Therapy in Treatment-Naïve Patients section